The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

PDL BioPharma Announces Resignation of Chief Financial Officer

Monday, December 03, 2012

PDL BioPharma Announces Resignation of Chief Financial Officer16:02 EST Monday, December 03, 2012INCLINE VILLAGE, Nev., Dec. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Bruce Tomlinson has resigned his position as vice president and chief financial officer of PDL due to personal reasons.  His resignation is effective as of November 30, 2012.  The company will begin a search for a new CFO. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)"On behalf of the team at PDL, I would like to thank Bruce for his contributions and insights and wish him well in his future endeavors," stated John McLaughlin, president and chief executive officer of PDL."In recent months, PDL completed three transactions related to its campaign to bring in new revenue generating assets, and it has been a pleasure to be a part of PDL and its recent accomplishments," stated Mr. Tomlinson.  "I wish PDL, its team and its shareholders continued success."About PDL BioPharmaPDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com. NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.  SOURCE PDL BioPharma, Inc.For further information: John McLaughlin, PDL BioPharma, Inc., +1-775-832-8500, john.mclaughlin@pdl.com; or Jennifer Williams, Cook Williams Communications, Inc., +1-360-668-3701, jennifer@cwcomm.org